Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection
Sphere Bio, a leading provider of innovative picodroplet-based microfluidics solutions for functional single-cell analysis and isolation, today announced the launch of the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit, the first multiplexed assay developed specifically for the Company’s new Cyto-Mine® Chroma platform.1
Sphere Fluidics Rebrands to Sphere Bio
Sphere Fluidics today announced its rebranding to Sphere Bio. The name change marks a significant milestone in the Company’s development, reflecting its transition from a leading droplet-based microfluidics innovator to an established commercial provider of integrated life sciences tools and solutions.
